Coronavirus

Steven Furr, MD, discusses how communication between clinicians and patients is crucial to combatting vaccine hesitancy this upcoming respiratory virus season.

Of the 25 routine lab tests studied, none proved clinically useful for diagnosing COVID-19, even among participants with a high long COVID symptom burden.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The rate of ME/CFS was similar (3% to 4%) at 3 through 12 months for study participants who tested positive and negative for COVID-19.

Ziyad Al-Aly, MD, and colleagues link 70% of the drop in cases to vaccine availability but caution the risk for long COVID remains significant.

Researchers also found that a lower proportion of individuals were diagnosed with long COVID following reinfection than after initial infection.

Tochi Iroku-Malize, MD, discusses the ACIP's updated recommendations for immunization against COVID-19, influenza, and RSV.

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

Individuals 6 months and older should receive updated COVID-19 and influenza vaccines for the 2024-2025 respiratory virus season, the agency recommended.

Your daily dose of the clinical news you may have missed.

In part the National Academies describe long COVID as "a chronic, systemic disease state with profound consequences." The report provides a working definition.

Your daily dose of the clinical news you may have missed.

The investigational combination vaccine elicited higher immune responses vs licensed comparator vaccines in 2 independent age groups, the company said.

The over-the-counter antigen test, for use at home or at point of care, discriminates between SARS-CoV-2 and influenza A and B in 15 minutes.

Your daily dose of the clinical news you may have missed.

Data presented at ACOG 2024 suggest SARS-CoV-2 infection early in pregnancy can lead to a higher likelihood of preeclampsia, as well as more severe disease.

Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.

Your daily dose of the clinical news you may have missed.

Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.

Your daily dose of the clinical news you may have missed.

In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.

Your daily dose of the clinical news you may have missed.

The mRNA bivalent vaccine candidate produced a "more robust" immune response vs Spikevax and particularly in adults over the age of 65 years, said Moderna.

New research highlights another benefit of COVID-19 vaccination, reported researchers.